Medical supervised duodenal-enteral feeding for the treatment of overweight and obesity: MESUDEFT / Nutrición duodenoenteral médicamente supervisada para el tratamiento del sobrepeso y la obesidad: MESUDEFT

Background: the development of specialised nutritional support techniques allows the maintenance of an adequate supply of nutrients in those patients in whom oral feeding is not possible or is insufficient in relation to their requirements, trying to improve the quality of life, especially in those with chronic diseases. Methods: single-center clinical study carried out in a clinical-nutritional center consisting of a medically supervised nasogastric-duodenal tube feeding treatment for overweight, obesity and increased body fat percentage in patients requiring it by means of duodeno-enteral feeding, expecting losses of more than 10 %. Results: twenty-nine patients completed the protocol (20.4 % male and 79.6 % female) with a mean age of 38 years (SD: 12.4); 87.2 kg (SD: 18.5) mean weight; 37.9 kg (SD: 4.8) mean iFat%; 32.4 (SD: 5.4) iMean body mass index (BMI); 100 cm (SD: 16.0) iMean waist; 113.6 cm (SD: 10.4) iMean hip; 33.8 cm (SD: 3.9) iMean upper arm circumference; 65.5 cm (SD: 7.5) iMean thigh circumference; 9.7 (SD: 4.8) iVisceral fat index; and 22.9 days (SD: 13.9) mean treatment. A mean of 22.9 (SD: 13.9) days of MESUDEFT influences weight loss, fat loss, visceral fat loss and decreased arm, hip and thigh circumferences (p < 0.05) (i: initial). Conclusions: MESUDEFT is shown to be an effective alternative as a sole treatment or as an adjunct prior to bariatric surgery for obesity or overweight treatment with a minimum of 10 % loss of BMI and fat mass at completion and 3-6 months follow-up.(AU)

Antecedentes: el desarrollo de técnicas especializadas de soporte nutricional permite mantener un aporte adecuado de nutrientes en aquellos pacientes en los que la alimentación oral no es posible o es insuficiente en relación a sus requerimientos, intentando mejorar la calidad de vida, especialmente de aquellos con enfermedades crónicas. Métodos: estudio clínico unicéntrico prospectivo realizado en un centro clínico-nutricional consistente en un tratamiento con alimentación por sonda nasogástrica-duodenal médicamente supervisado para el sobrepeso, la obesidad y el aumento del porcentaje de grasa corporal en pacientes que lo requieran mediante alimentación duodenoenteral, durante un mes aproximado, con previsión de pérdidas superiores al 10 % y con control posterior entre los tres y los seis meses siguientes. Resultados: veintinueve pacientes completaron el protocolo (20,4 % varones y 79,6 % mujeres) con una edad media de 38 años (DE: 12,4); 87,2 kg (DE: 18,5) iPeso medio; 37,9 kg (DE: 4,8) iGrasa% media; 32,4 (DE: 5,4) iIMC medio; 100 cm (DE: 16,0) iCintura media; 113,6 cm (DE: 10,4) iCadera media; 33,8 cm (DE: 3,9) iCircunferencia braquial media; 65,5 cm (DE: 7,5) circunferencia muslo media; 9,7 (DE: 4,8) iíndice de grasa visceral; y 22,9 días (DE: 13,9) de tratamiento medio. Una media de 22,9 (DE: 13,9) días de MESUDEFT influye en la pérdida de peso, la pérdida de grasa, la pérdida de grasa visceral y la disminución de las circunferencias del brazo, la cadera y el muslo (p < 0,05) (i: inicial). Conclusiones: MESUDEFT se muestra como una alternativa eficaz como tratamiento único o como coadyuvante previo a la cirugía bariátrica de la obesidad o tratamiento del sobrepeso con una pérdida mínima del 10 % del índice de masa corporal (IMC) y de la masa grasa al finalizar y con control durante los siguientes 3-6 meses.(AU)

Medical supervised duodenal-enteral feeding for the treatment of overweight and obesity: MESUDEFT.

BACKGROUND: the development of specialised nutritional support techniques allows the maintenance of an adequate supply of nutrients in those patients in whom oral feeding is not possible or is insufficient in relation to their requirements, trying to improve the quality of life, especially in those with chronic diseases. METHODS: single-center clinical study carried out in a clinical-nutritional center consisting of a medically supervised nasogastric-duodenal tube feeding treatment for overweight, obesity and increased body fat percentage in patients requiring it by means of duodeno-enteral feeding, expecting losses of more than 10 %. RESULTS: twenty-nine patients completed the protocol (20.4 % male and 79.6 % female) with a mean age of 38 years (SD: 12.4); 87.2 kg (SD: 18.5) mean weight; 37.9 kg (SD: 4.8) mean iFat%; 32.4 (SD: 5.4) iMean body mass index (BMI); 100 cm (SD: 16.0) iMean waist; 113.6 cm (SD: 10.4) iMean hip; 33.8 cm (SD: 3.9) iMean upper arm circumference; 65.5 cm (SD: 7.5) iMean thigh circumference; 9.7 (SD: 4.8) iVisceral fat index; and 22.9 days (SD: 13.9) mean treatment. A mean of 22.9 (SD: 13.9) days of MESUDEFT influences weight loss, fat loss, visceral fat loss and decreased arm, hip and thigh circumferences (p < 0.05) (i: initial). CONCLUSIONS: MESUDEFT is shown to be an effective alternative as a sole treatment or as an adjunct prior to bariatric surgery for obesity or overweight treatment with a minimum of 10 % loss of BMI and fat mass at completion and 3-6 months follow-up.